Introduction {#Sec1}
============

Mucins are high molecular weight glycoproteins with oligosaccharides attached to serine or threonine residues of the mucin core protein backbone by *O*-glycosidic linkages (Hollingsworth and Swanson [@CR36]). These proteins are produced by various types of epithelial cells. In the past two decades, core proteins for human mucins (MUC1--MUC8, MUC12--13, MUC15--17, MUC19--21) have been identified and categorized as membrane-associated mucins (MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20, and MUC21) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6, MUC7, MUC8, and MUC19) (Chen et al. [@CR11]; Higuchi et al. [@CR31]; Hollingsworth and Swanson [@CR36]; Itoh et al. [@CR39]; Lehmann et al. [@CR53]; Moniaux et al. [@CR66]). Mucins are responsible for the physical properties of mucus gels and are involved in epithelial cell protection and maintenance of the local molecular microenvironment (Bhaskar et al. [@CR6]; Ho et al. [@CR35]; Linden et al. [@CR57], [@CR58]). However, transmembrane mucins, in particular, are overexpressed and aberrantly glycosylated in most cases of adenocarcinoma and are also associated with invasive proliferation of tumors and a poor outcome (Hollingsworth and Swanson [@CR36]; Kufe [@CR50]). Immunohistochemical studies of mucin expression in human tumors have demonstrated that expression of MUC1 and MUC4 is a poor prognostic factor, whereas MUC2 expression is associated with a favorable outcome in neoplasms including pancreatic ductal adenocarcinomas. MUC5AC is a common neoplastic marker in pancreatobiliary neoplasms (Nagata et al. [@CR70]; Yonezawa et al. [@CR127], [@CR128]).

Epigenetic regulation, including DNA methylation, has been a focus of studies of mucin gene expression. CpG methylation in genomic DNA plays an important role in gene regulation and especially in gene silencing, and generally, the promoter region of a transcribed gene is hypomethylated (Bird [@CR7]). There are three primary DNA methyltransferases (DNA methyltransferase 1 (DNMT1), DNMT3A, and DNMT3B). DNMT1 methylates hemi-methylated DNA and is essential for maintaining methylation patterns. DNMT3A and DNMT3B target previously unmethylated CpGs (Oka et al. [@CR76]; Rodriguez-Paredes and Esteller [@CR86]). Aberrant DNA methylation is strongly associated with human cancer and may serve as a good risk marker for future tumor development and as a target for chemotherapy (Hiraki et al. [@CR32]; Lenhard et al. [@CR54]; Matsubayashi et al. [@CR61]).

Nucleosomes are the basic unit of DNA packaging in eukaryotes, and each nucleosome consists of approximately 147 bp DNA and a histone octamer (core histones) (White et al. [@CR113]). The core histones have an N-terminal amino acid tail of about 20--35 residues in length that is rich in basic amino acids (Munshi et al. [@CR68]). Posttranslational modification of histone tails plays a critical role in epigenetic silencing (Kondo et al. [@CR48]; Wolffe and Matzke [@CR116]). Histone tails are subject to many different chemical modifications, including methylation, acetylation, and phosphorylation (Marmorstein [@CR60]). Such modifications affect the access of regulatory factors and alter histone complexes with chromatin, thereby influencing gene expression. Acetylation of lysines 9, 14, and 27 of histone H3 is associated with euchromatin formation (less condensed), and acetylation of promoter-proximal histones is associated with gene expression (Shi et al. [@CR93]). In contrast, methylation of lysine 9 of histone H3 (H3-MeK9) facilitates formation of heterochromatin (highly condensed), and elevated levels of H3-MeK9 at promoter sequences are associated with suppression of gene expression (Mutskov and Felsenfeld [@CR69]; Nguyen et al. [@CR73]). Methylation of lysine 27 of histone H3 is also a marker for constitutive and facultative heterochromatin (Alvarez-Venegas and Avramova [@CR1]). Another histone modification, methylation of K4 of histone H3, localizes to sites of active transcription, and this modification may stimulate transcription. Combinations of histone modifications at different residues may act synergistically or antagonistically to affect gene expression (Liang et al. [@CR56]).

Gene expression may also be regulated by micro-RNAs (miRNAs), which are a class of small non-coding RNAs of approximately 22 nucleotides (He and Hannon [@CR29]). In mammals, miRNAs are incorporated into RNA-induced silencing complexes and bind imperfectly to the 3′ untranslated region (3′-UTR) of target messenger RNAs (mRNAs) and repress translation (Nakahara and Carthew [@CR71]). Epigenetic regulation of small non-coding RNAs plays a critical role in the modulation of mammalian gene expression (Lujambio and Esteller [@CR59]; Zhang et al. [@CR130]). In addition, miRNAs have been reported to regulate both tumor suppressor genes and oncogenes (Medina and Slack [@CR63]; Saito and Jones [@CR90]).

Pathological events such as carcinogenesis can be caused by alteration in established methylation patterns or dysregulation of chromatin remodeling, both of which can result in significant and consequential changes in gene expression (Das and Singal [@CR13]; DeAngelis et al. [@CR14]). Thus, investigation of DNA methylation, chromatin modification, and miRNA expression is important for diagnosis of carcinogenic risk and prediction of outcomes in patients with cancer.

In this review, we discuss current views on epigenetic mechanisms of human mucin family genes, and we examine the possible clinical applications of this epigenetic information (Table [1](#Tab1){ref-type="table"}). Table 1CpGs, histone modifications, and other factors or miRNAs that affect the expression of epigenetically regulated mucin genesMucinsPromoter methylation sitesHistone modificationFactors or miRNAMUC1−70 to +20H3-me2K9, aceK9miR-125b, miRNA-145, miR-1226MUC2−3,269, −3,199, −2,331, −1,912, −338 to +158H3-me2K4, me3K4, meK9, me2K9, aceK9, me2K27, aceK27, H3-ace, H4-aceDNMT1, HDAC2MUC3A−345 to −75N.D.N.D.MUC4−121 to −81^a^H3-ace, me2K9, aceK9, me3K27Sp1, DNMT3A, DNMT3B, HDAC1, HDAC3−170 to −102^b^MUC5AC−3,718 to −3,670H3-me2K9, aceK9N.D.MUC5B−2,677/−2,163H3-me2K4, me3K4, meK9DNMT1, HDAC2−434/−421me2K9, aceK9, me2K27, aceK27MUC17−179 to +52H3-me2K9, aceK9N.D.*ND* not determined^a^Region reported by Vincent et al.^b^Region reported by Yamada et al.

Analysis of DNA methylation and histone modification {#Sec2}
====================================================

There are two main methods for genome-wide analysis of DNA methylation patterns, which are referred to as bisulfite sequencing and MassARRAY analysis. In DNA methylation analysis, sodium bisulfite is used to distinguish between methylated and unmethylated cytosine. Bisulfite treatment of DNA converts cytosine to uracil, but does not alter methylated cytosine. In bisulfite sequencing, polymerase chain reaction (PCR) amplification of converted DNA is used to replace the uracil with thymine, and the PCR product is analyzed by Sanger dideoxy terminator sequencing (Zilberman and Henikoff [@CR132]). This method is a standard tool in genome-wide CpG methylation analysis, but is relatively time-consuming and costly. MassARRAY® quantitative methylation analysis (Sequenom Inc.) is based on the bisulfite conversion biochemistry followed by PCR and base-specific cleavage. The cleavage products are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (Ehrich et al. [@CR17]). This combination of methods gives a highly accurate, sensitive, and high-throughput approach for quantitative analysis of DNA methylation.

Meanwhile, methylation-specific PCR (MSP), real-time quantitative MSP with SYBR green or probe (QMSP), and pyrosequencing can be used for the detection of methylation status of specific regions involved in the regulation of gene transcription. MSP and QMSP are bisulfite conversion-based PCR techniques, in which two PCR reactions are carried out using unmethylated DNA primers (U primer) and methylated DNA primers (M primer). MSP and QMSP are rapid and inexpensive methods for detection of the CpG methylation status, but only a limited number of CpGs in a primer sequence can be detected using these methods. Pyrosequencing is a DNA sequencing technique that is based on the detection of released pyrophosphate (PPi) during DNA synthesis (Ronaghi [@CR87]). Pyrosequencing is an accurate and fast method for quantification of CpG methylation.

Chromatin immunoprecipitation (ChIP) analysis is a useful technique for investigating histone modifications and/or protein--DNA interactions. In this procedure, formaldehyde-treated chromatin nucleoprotein complexes are sonicated to reduce the sizes of the DNA fragments to 300 to 500 bp. This is followed by immunoprecipitation using specific antibodies against target histone modifications or transcriptional factors, with subsequent amplification of the immunoprecipitated DNA by PCR (Fullwood and Ruan [@CR18]).

Functional role and epigenetic regulation mechanisms of mucin genes {#Sec3}
===================================================================

MUC1 {#Sec4}
----

The MUC1 transmembrane glycoprotein (gene cluster on chromosome 1q21) is expressed at a basal level by normal ductal epithelial cells of secretory organs, including pancreas, breast, lung, and gastrointestinal tract (Lan et al. [@CR51]), and overexpressed and aberrantly glycosylated in most cases of adenocarcinoma (Patton et al. [@CR80]). An elevated level of MUC1 protein plays a role in tumor progression, especially in the process of metastasis (Hollingsworth and Swanson [@CR36]; Kufe [@CR50]). Our clinicopathological studies have demonstrated that MUC1 expression is a poor prognostic factor in various human neoplasms (Higashi et al. [@CR30]; Kitamura et al. [@CR47]; Sagara et al. [@CR89]; Takao et al. [@CR101]; Tamada et al. [@CR102]; Utsunomiya et al. [@CR106]).

The epigenetic mechanisms of *MUC1* were not examined for more than a decade after initial methylation analysis of the *MUC1* coding region (Zrihan-Licht et al. [@CR133]). However, our recent comprehensive DNA methylation analysis revealed that *MUC1* gene expression is regulated by DNA methylation and histone H3 lysine 9 (H3-K9) modification at the *MUC1* promoter for the first time (Yamada et al. [@CR118]). In the approximately 3,000 bp of the *MUC1* promoter region, there are 184 CpG sites. Analysis of all these sites using the MassARRAY compact system for base-specific cleavage of nucleic acids was performed in MUC1-positive and MUC1-negative breast, pancreas, and colon cancer cell lines. The methylation status of nine CpG sites near the transcriptional start site and histone H3-K9 modification in the vicinity of the start site were both related to *MUC1* gene expression. Collectively, a series of epigenetic analyses revealed that DNA demethylation, histone H3-K9 demethylation, and histone H3-K9 acetylation in the 5′-flanking region of *MUC1* might all be necessary for *MUC1* gene expression (Fig. [1](#Fig1){ref-type="fig"}). Most recently, downregulation of MUC1 expression by micro-RNA has been reported by several groups (Jin et al. [@CR40]; Rajabi et al. [@CR84]; Sachdeva and Mo [@CR88]). Sachdeva and Mo showed that miR-145 directly targets *MUC1* by interaction with the 3**′**-UTR and found that miR-145 acts as a tumor suppressor in part by affecting invasion and metastasis by targeting MUC1 (Sachdeva and Mo [@CR88]). Moreover, Suh et al. found that miR-145 is silenced by DNA hypermethylation at the miR-145 promoter region in prostate cancer cells and that 5-azadC treatment induced miR-145 expression in prostate cancer cell lines with miR-145 hypermethylation (Suh et al. [@CR99]). In breast cancer cells, Rajabi et al. indicated that miR-125b suppresses translation of the MUC1 and that miR-125b thereby functions as a tumor suppressor (Rajabi et al. [@CR84]). Jin et al. showed that MUC1 expression is suppressed by miR-1226 and that miR-1226-induced downregulation of MUC1 is correlated with cell death of MUC1-positive breast cancer cells (Jin et al. [@CR40]). These findings suggest the possible functional importance of MUC1 under both physiological and pathological conditions. Fig. 1Schematic model of *MUC1* gene regulation through epigenetic modifications. Open chromatin is characterized by an unmethylated status of the *MUC1* promoter and histones with acetylated H3-K9. This may allow assembly of transcription factors and transcription by RNA polymerase. DNA methylation and histone deacetylation result in condensation of chromatin into a compact state that is inaccessible to transcription factors. The *MUC1* gene can also be posttranscriptionally regulated by miRNAs (miR-125b, miR-145, or miR-1226) that target the 3′-UTR of *MUC1* mRNA and cause mRNA degradation or translational repression

MUC2 {#Sec5}
----

MUC2 is a gel-forming secretory mucin that is expressed in many organs, including the colon, small intestine, and respiratory tract. The corresponding gene has been mapped to human chromosome 11p15 (Chang et al. [@CR10]; Desseyn et al. [@CR16]). Alteration in the protection and lubrication of the intestinal mucosal surface due to a lack of MUC2 might induce an increase of bacterial flora with pro-carcinogenic effects, result in the release of intestinal mucosa-derived factors that are normally depressed by MUC2-stimulating pro-carcinogenic factors, or lead to the destruction of the physical barrier to dietary carcinogens. Loss of MUC2 might also compromise signaling that contributes to epithelial differentiation and proliferation through contacts with membrane-bound mucins or alter the differentiation program of the intestinal mucosa, resulting in an increased probability of tumor formation. Muc2 knockout mice frequently develop adenomas in the small intestine that progress to invasive adenocarcinoma (Velcich et al. [@CR109]). However, high levels of MUC2 expression seen in indolent human pancreatobiliary neoplasms (Higashi et al. [@CR30]; Horinouchi et al. [@CR37]; Nakamura et al. [@CR72]; Yamashita et al. [@CR122]; Yonezawa et al. [@CR125]) are associated with a favorable prognosis (Kitamura et al. [@CR47]; Osako et al. [@CR78]; Tamada et al. [@CR102]; Utsunomiya et al. [@CR106]; Yonezawa et al. [@CR125], [@CR127]; Yonezawa and Sato [@CR124]).

Epigenetic analysis of the *MUC2* gene promoter region has been widely studied (Gratchev et al. [@CR21]; Hanski et al. [@CR27]; Mesquita et al. [@CR64]; Siedow et al. [@CR97]). We have determined the detailed methylation status of a wide area of the *MUC2* promoter in breast, lung, pancreas, and colon cancer cell lines using bisulfite genomic sequencing and MassARRAY analysis (Hamada et al. [@CR25]; Yamada et al. [@CR120]). Our results indicated that CpG methylation near the *MUC2* transcriptional start site (−338 to +158) plays a critical role in *MUC2* gene expression. ChIP assays were also performed using anti-dimethyl-H3-K4/K9/K27, anti-trimethyl-H3-K4/K9, and anti-acetyl-H3-K9/K14/K27 antibodies and revealed that histone H3-K4 methylation, histone H3-K9 dimethylation, and histone H3-K9/K27 acetylation in the 5′-flanking region of the *MUC2* may be necessary for gene expression (Yamada et al. [@CR117]). Moreover, treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-azadC) and/or a histone deacetylase inhibitor, trichostatin A (TSA) decreased the DNA methylation level in MUC2-negative cells, whereas histone H3-K4/K9 methylation and H3-K9/K27 acetylation were changed to the levels in MUC2-positive cells (Yamada et al. [@CR117]). In the distal region of the *MUC2* promoter, the CpG sites at −3,269, −3,199, −2,331, and −1,912 was associated with expression of *MUC2* (Vincent et al. [@CR110]). Vincent et al. also showed that *MUC2* expression is controlled by HDAC2-enhanced DNMT1 and that methylation of the *MUC2* promoter markedly impaired its activation by the methylation-insensitive transcription factor SP1 (Vincent et al. [@CR110]). These studies suggest that epigenetic mechanisms are tightly correlated with *MUC2* expression in epithelial cells in various organs. Attempts to apply these findings to clinical samples have begun, and it has been shown that hypomethylation of *MUC2* plays an important role in the high level of *MUC2* expression in mucinous colorectal cancer (Okudaira et al. [@CR77]).

MUC3A {#Sec6}
-----

MUC3A was identified and mapped to a mucin cluster on chromosome 7q22 and categorized as a membrane-associated mucin (Crawley et al. [@CR12]; Gum et al. [@CR22], [@CR23]; Leroy et al. [@CR55]). An association between MUC3A expression and poor prognosis has been shown in pancreatic, breast, gastric, and renal cancers (Leroy et al. [@CR55]; Park et al. [@CR79]; Rakha et al. [@CR85]; Wang and Fang [@CR112]). However, little is known about the functional role of MUC3A in cancer pathology, and understanding the expression mechanisms of MUC3A may be a key step in developing new strategies for cancer diagnosis and treatment.

In the *MUC3A* proximal promoter (−620 to +209), the methylation status of 30 CpG sites in breast, lung, pancreas, and colon cancer cells were examined by MassARRAY analysis (Kitamoto et al. [@CR45]). The methylation status showed a good correlation with the level of *MUC3A* expression. MUC3A-negative/low cell lines were hypermethylated in the vicinity of the transcriptional start site (−345 to −75), whereas MUC3A-positive cell lines showed hypomethylation at the same sites. In contrast, restoration of MUC3A mRNA was observed after TSA treatment, although there was no correlation of *MUC3A* expression with histone modification at H3K4-Me2/Me3 or H3K9-Me2/Ac. These results suggest that histone H3-K4 and H3-K9 do not play critical roles in *MUC3A* regulation. Although the roles of MUC3A in cancer development are still unclear, some evidence suggests that MUC3A expression is associated with a poor prognosis in many tumor types. Thus, the methylation status of the *MUC3A* promoter may be a novel epigenetic marker for the diagnosis of carcinogenic risk and prediction of outcomes for patients with cancer.

MUC4 {#Sec7}
----

MUC4 is a large transmembrane mucin with a very long glycosylated extracellular domain that is expressed in various normal tissues. The corresponding gene has been mapped to a gene cluster at chromosome 3q29 (Audie et al. [@CR3], [@CR4]; Buisine et al. [@CR9]; Gipson et al. [@CR20]). MUC4 is often overexpressed in epithelial cancers, as for MUC1, and is associated with invasive proliferation of tumors and a poor outcome (Saitou et al. [@CR91]; Shibahara et al. [@CR95]; Tamada et al. [@CR103]; Tsutsumida et al. [@CR105]). *MUC4* serves as a intramembrane ligand for the receptor tyrosine kinase ErbB2, which is a transmembrane glycoprotein encoded by the *c-ErbB-2* proto-oncogene and has a tyrosine kinase domain that is highly homologous with the epidermal growth factor receptor (Yamamoto et al. [@CR121]).

Jonckheere et al. ([@CR41]) found that treatment with TSA restored *MUC4* mRNA expression in MUC4-negative pancreatic cancer cells. Singh et al*.* also showed that the expression level of *MUC4* was restored by treatment with 5-azadC and sodium butyrate, an inhibitor of histone deacetylase, in MUC4-negative prostate cancer cells, and suggested that *MUC4* is regulated epigenetically (Singh et al. [@CR98]). An investigation of the detailed epigenetic mechanisms of *MUC4* expression showed that regulation of *MUC4* expression involves both DNA methylation (particularly cytosines at −81, −93, −102, −113, and −121) and histone H3 modification (including H3-K9 and H3-K27 in the *MUC4* 5′-UTR) mediated by DNA methyltransferases (DNMT3A and DNMT3B) and histone deacetylases (HDAC1 and HDAC3) in pancreatic and gastric epithelial cancer cell lines (Vincent et al. [@CR111]). SP1 binding to the *MUC4* promoter (−276/−271 and −166/−156) was also found to participate in the regulation of *MUC4* gene expression (Vincent et al. [@CR111]).

We used quantitative MassARRAY methylation analysis to examine the methylation status of 92 CpG sites in the *MUC4* promoter (−3,629 to +29) in breast, lung, pancreas, and colon cancer cell lines (Yamada et al. [@CR119]). In 10 cancer cell lines, methylation of 5 CpG sites in the 5′-flanking region of *MUC4* (−170 to −102) was associated with the expression of *MUC4*. Five CpG sites (−121 to −81) had previously been correlated with the expression of *MUC4* in these cells (Vincent et al. [@CR111]), but 2 of these CpG sites (−93 and −81) were unrelated to expression of *MUC4* in our study. This issue may be resolved by the use of different analytical methods in future studies. Most recently, an examination of the relationships among *MUC4* promoter methylation, pancreatic cancer progression, and *MUC4* mRNA expression in clinical tissue samples led to the suggestion that aberrant *MUC4* promoter hypomethylation may be involved in pancreatic carcinogenesis and malignant development of pancreatic ductal adenocarcinoma (Zhu et al. [@CR131]).

MUC5AC and MUC5B {#Sec8}
----------------

MUC5AC is a gastric-type secreted gel-forming mucin that is located in the chromosome 11p15 region in a cluster of complex mucin genes (Kim et al. [@CR44]). Although MUC5AC expression in the surface mucous cells in normal gastric mucosa served as a positive control for expression, MUC5AC are never expressed in normal pancreatic tissue. In contrast, MUC5AC has high de novo expression in many types of precancerous lesions of pancreatic ductal adenocarcinoma (PDAC), including pancreatic intraepithelial neoplasia (PanIN) (Nagata et al. [@CR70]), intraductal papillary mucinous neoplasm of the pancreas (Yonezawa et al. [@CR126]), and mucinous cystic neoplasm of the pancreas (Gratchev et al. [@CR21]; Handra-Luca et al. [@CR26]). MUC5AC is also expressed in the lesions of bile duct adenocarcinoma, including biliary intraepithelial neoplasia, mucin-producing bile duct tumor, intraductal papillary neoplasm of the bile duct, and bile duct cystic neoplasm (Shibahara et al. [@CR94]; Zen et al. [@CR129]). Thus, MUC5AC expression may be a useful marker for early detection of pancreatobiliary neoplasms.

Similar to MUC5AC, MUC5B is also a gel-forming mucin and the corresponding gene has been mapped to chromosome 11p15 (Desseyn et al. [@CR15]). MUC5B is widely expressed in normal tissues in the respiratory and digestive tract (Andrianifahanana et al. [@CR2]). Little is known about MUC5B, but aberrant MUC5B expression has been observed in inflamed or cancerous tissues (Andrianifahanana et al. [@CR2]; Kamio et al. [@CR43]; Pinto-de-Sousa et al. [@CR83]).

Previous studies on the epigenetics of human *MUC5AC* gene expression have focused on a 1.3-kb promoter region and found little influence of epigenetic regulation, despite restoration of *MUC5AC* mRNA expression in cancer cells by 5-azadC treatment (Ho et al. [@CR34]; Vincent et al. [@CR110]). In contrast, a recent study has shown that methylation in the "CpG island shore" distal to CpG islands is correlated with silencing of numerous genes (Irizarry et al. [@CR38]). In the *MUC5AC* promoter region, there is no CpG site from −1.3 to −3.1 kb, but it is of interest that CpG sites reappear from about −3.1 kb onwards. This led us to widen the scope of our study to examine epigenetic mechanisms over about 4.0 kb of the *MUC5AC* promoter (Yamada et al. [@CR120]). The DNA methylation status of the *MUC5AC* promoter (−3,855 to +321) in 10 cancer cell lines (breast, lung, pancreas, and colon) was mapped using MassARRAY analysis. The results showed that the CpG methylation status of the *MUC5AC* promoter from −3,718 to −3,670 is correlated with *MUC5AC* expression. These results were also consistent with data from pyrosequencing analysis. The modification status of histone H3-K9 in the distal promoter region (−3,718 to −3,670) was also tightly correlated with expression of *MUC5AC*.

Epigenetic regulation of *MUC5B* has been shown in several studies (Perrais et al. [@CR82]; Van Seuningen et al. [@CR108]). Detailed epigenetic analysis of the *MUC5B* promoter region (2.3 kb), including bisulfite sequencing and ChIP assays, in esophageal, gastric, pancreatic, and colon cancer cell lines showed that *MUC5B* is highly sensitive to DNA methylation and histone modifications in the *MUC5B* distal promoter (CpG sites at −2,677/−2,163), as well as at cytosines at −434 and −421 (Vincent et al. [@CR110]). This study also indicated that *MUC5B* expression is regulated by HDAC2-enhanced DNMT1 and that methylation of the *MUC5B* promoter markedly impaired its activation by SP1 (Vincent et al. [@CR110]). Methylation profiling of the *MUC5B* distal promoter using bisulfite sequencing and pyrosequencing has also been performed in normal lung and in MUC5B-negative lung cancer tissues (Van Seuningen and Vincent [@CR107]).

MUC6 {#Sec9}
----

MUC6 was originally isolated from a gastric cDNA library and mapped to a mucin cluster on chromosome 11p15 (Toribara et al. [@CR104]). High expression of MUC6 is observed in gastric mucosa, duodenal Brunner's glands, gall bladder, seminal vesicles, pancreatic centroacinar cells and ducts, and periductal glands of the common bile duct. Focal expression is seen in basal endometrial and endocervical glands. MUC6 is also highly expressed in pancreatic cancers and cholangiocarcinomas and focally expressed in endocervical adenocarcinomas (Bartman et al. [@CR5]). In breast tissues, Matsukita et al. have shown a correlation between MUC6 expression and mucinous carcinoma of the breast, suggesting that high expression of MUC6, as well as MUC2, in mucinous carcinoma may act as a barrier to cancerous growth and result in less aggressive biological behavior (Matsukita et al. [@CR62]).

Epigenetic regulation of *MUC6* seems to be unlikely, since treatment with 5-aza or TSA did not lead to restoration of *MUC6* mRNA in MUC6-negative cell lines, despite the identification of three key methylated cytosines at −282, −271, and −72 by bisulfite sequencing (Vincent et al. [@CR110]). Vincent et al. suggested that repression of *MUC6* in cancer cells is rather due to the absence of necessary transcription factors or by an unknown repressive mechanism than to the methylation of its promoter (Vincent et al. [@CR110]).

MUC16 (CA125) {#Sec10}
-------------

MUC16 (CA125) was identified and mapped to a mucin cluster on chromosome 19p13 and categorized as a transmembrane mucin (O'Brien et al. [@CR74]). Because highly O-glycosylated repeats are the landmark of the mucin family of glycoproteins, CA125 was also named MUC16. MUC16 is overexpressed in many carcinomas (e.g., ovarian cancer, uterine cancer, pancreatic cancer, and biliary cancer) and is known as a tumor marker that is associated with poor prognosis (O'Brien et al. [@CR74], [@CR75]; Yin and Lloyd [@CR123]).

The structure and function of MUC16 have been well studied, but the mechanisms of regulation of *MUC16* expression have yet to be clarified. We have examined the epigenetic status of the *MUC16* 5′-flanking region in breast, lung, pancreas, and colon cancer cells using MassARRAY analysis and ChIP assays (unpublished data). Treatment with 5-azadC and TSA showed restoration of *MUC16* mRNA expression, but MassARRAY and ChIP results showed no correlation between histone H3 modification and MUC16 gene expression. Our findings suggest that epigenetic mechanisms are involved in the regulation of *MUC16* expression in cancer cells, but DNA methylation and histone H3-K9 modification in the *MUC16* 5′-flanking region are unlikely to regulate *MUC16* transcription directly. It will be necessary to perform promoter analysis to clarify the details of the expression mechanism of MUC16, which is a poor prognostic factor in patients with cancer.

MUC17 {#Sec11}
-----

MUC17 glycoprotein was identified and mapped to a mucin cluster at chromosome 7q22 and categorized as a membrane-associated mucin (Gum et al. [@CR24]; Williams et al. [@CR114]). MUC17 is mainly expressed in the digestive tract, including the duodenum, ileum, and transverse colon (Gum et al. [@CR24]; Moehle et al. [@CR65]), but its physiological function is unclear. Aberrant MUC17 expression is observed in PDAC, compared to no expression in the normal pancreas or in pancreatitis (Moniaux et al. [@CR67]), and MUC17 is an independent prognostic factor associated with lymph node metastasis in PDAC (Hirono et al. [@CR33]).

We performed MassARRAY quantitative methylation analysis in human cancer cell lines (breast, lung, pancreas, and colon) to determine the methylation status of CpG islands in the *MUC17* 5′-flanking region (−620 to +209) (Kitamoto et al. [@CR46]). Five CpG sites (−179 to +52) involved in MUC17 expression were identified and these results were consistent with MSP data. To examine the relationship between DNA methylation and histone H3 modification, ChIP assays were performed. Dimethyl-H3-K9 was found in MUC17-negative/low cells, whereas histone H3-K9 was more highly acetylated in MUC17-positive cells. The level of *MUC17* mRNA expression was restored by treatment with 5-azadC or TSA. Using MSP analysis, we also investigated the methylation status of normal and cancerous pancreatic tissues from patients with PDAC and found that the methylation status in the five CpG sites of the *MUC17* promoter (−179 to +52) was consistent with the expression of MUC17 at both the mRNA and protein levels. Although further studies are needed to clarify these relationships, our findings indicate that the methylation status of the *MUC17* promoter could be a novel epigenetic marker for diagnosis of PDAC. Moreover, miRNA microarray analysis in 11 cancer cell lines revealed 5 candidates with a significant relationship with the regulation of *MUC17* expression: miR-17, miR-20a, miR-20b, miR-30c, miR-30e, using target prediction based on the miRBase. Of these candidates, it is unclear which are authentic miRNAs in vivo. Additional studies are required, but our data suggest that the *MUC17* gene might be regulated posttranscriptionally by miRNAs.

Conclusions and clinical perspectives {#Sec12}
=====================================

The epigenetic mechanisms of human mucin family genes are gradually emerging (Table [1](#Tab1){ref-type="table"}). However, establishment of clinical tests for cancer screening, diagnosis of carcinogenic risk, and tumor staging requires improved understanding of the roles of modifier enzymes (CpG methylation and chromatin) and epigenetic modifications accompanying tumor differentiation. An aberrant increase in both *MUC4* mRNA expression and hypomethylation frequency in the PanIN--PDAC progression modality has been shown (Zhu et al. [@CR131]), and increased DNMT1 expression may be involved in multistage pancreatic carcinogenesis from the precancerous stage to malignant progression of ductal carcinomas and may be a predictor of poor prognosis (Peng et al. [@CR81]). Further studies are needed to elucidate the relationships among expression levels of mucins, binding of transcriptional regulatory factors, and recruitment of DNMTs, HDACs, methylated DNA binding domain proteins, and polycomb group proteins.

Mucin expression is tissue- and cell-type specific (Yonezawa et al. [@CR127]), and these specificities may cause different forms of epigenetic regulation at different levels. For *MUC1* and *MUC4*, we were unable to show a relationship between DNA methylation status and expression of *MUC1* in the LS174T colon cancer cell line (Yamada et al. [@CR118], [@CR119]). However, expression of *MUC1* in Caco2 cells, which are derived from cancer cells of the same organ, was related to the DNA methylation status. Similarly, BxPC-3 pancreatic cancer cells with low MUC5AC expression had a high level of CpG methylation, whereas PANC1 cells (which have low or no MUC5AC expression) showed hypomethylation. Our results indicate that regulation of expression by DNA methylation is not organ specific, but varies in individual cell lines. Moreover, coordinated changes in DNA methylation and histone modification may be important for epigenetic regulation of mucin genes in cancer cell lines derived from various organs (Kitamoto et al. [@CR45], [@CR46]; Yamada et al. [@CR117], [@CR118], [@CR119]). However, further studies are needed to clarify how these different epigenetic changes are involved in tissue-specific mucin expression in cancer.

Many studies of epigenetic gene regulation have addressed tumor suppressor genes (Garinis et al. [@CR19]). Meanwhile, evidence for promoter hypomethylation of oncogenes has gradually emerged in tumors of several organs (Sato et al. [@CR92]; Sun et al. [@CR100]; Wolff et al. [@CR115]). Currently, epigenetic regulation of oncogenes is a phenomenon of interest. Transmembrane mucin genes associated with a poor prognosis (e.g., MUC1 and MUC4) may also be regulated by epigenetic mechanisms. In cancers like pancreatobiliary and lung carcinomas with a high potential for malignancy showing MUC1 and MUC4 high expression but no MUC2 expression (Yonezawa et al. [@CR127]), promoter CpG sites in transmembrane mucin genes like *MUC1* and *MUC4* associated with a poor outcome may be hypomethylated, while promoter CpG sites of *MUC2* associated with a favorable outcome may be hypermethylated, according to the data based on our studies using human cancer cells (Yamada et al. [@CR117], [@CR118], [@CR119]). Improved understanding of the regulatory mechanisms controlling these polar opposite events may enhance the understanding of epigenetic mechanisms associated with other oncogenes and tumor suppressor genes.

Posttranscriptional regulation of gene expression by miRNAs is attracting increased attention (Hartmann et al. [@CR28]; Krol et al. [@CR49]; Rajabi et al. [@CR84]). Among mucin genes, MUC1 expression has been shown to be directly downregulated by miR-145, with the further finding that miR-145 acts as a tumor suppressor in cell invasion and metastasis by targeting MUC1 (Sachdeva and Mo [@CR88]). miR-125b and miR-1226 have also been reported to target MUC1 expression (Jin et al. [@CR40]), and it is likely that these miRNAs could be attractive targets for therapeutic intervention in advanced cancers.

Epigenetic analysis of cancer-related genes in clinical specimens is relatively common, especially using DNA methylation analysis (Kamalakaran et al. [@CR42]; Okudaira et al. [@CR77]). There are several techniques for the evaluation of CpG methylation, but MSP, including quantitative MSP, is a leading strategy for the analysis of clinical samples (Lee et al. [@CR52]; Zhu et al. [@CR131]). However, MSP identifies only regions recognized by the primer sequence, and MassARRAY and pyrosequencing analysis are increasingly being used to overcome this problem (Shinojima et al. [@CR96]; Van Seuningen and Vincent [@CR107]). MassARRAY analysis permits high-throughput identification of methylation sites and semi-quantitative measurement at single or multiple CpG sites. Pyrosequencing is also a reliable technique for quantification of methylation at a single CpG site (Brakensiek et al. [@CR8]). Moreover, methylation analysis by these technologies gives highly reproducible quantification (Shinojima et al. [@CR96]; Van Seuningen and Vincent [@CR107]). In these techniques, however, as clinical samples include various components other than tumor cells, evaluation of the average percentage of methylation of the individual CpG sites is not easy. To permit analysis of discharged fluids, such as pancreatic juice, bile, or sputum, there is a need to develop the technique that allows the detection of individual CpG methylation patterns to be detected.
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